CSIMarket
 
Lexaria Bioscience Corp   (LEXX)
Other Ticker:  
 
 
Price: $3.9000 $0.05 1.299%
Day's High: $4.05 Week Perf: -37.6 %
Day's Low: $ 3.65 30 Day Perf: 50 %
Volume (M): 465 52 Wk High: $ 6.85
Volume (M$): $ 1,813 52 Wk Avg: $1.47
Open: $3.80 52 Wk Low: $0.65



 Market Capitalization (Millions $) 35
 Shares Outstanding (Millions) 9
 Employees -
 Revenues (TTM) (Millions $) -3
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Lexaria Bioscience Corp
Lexaria Bioscience Corp is a biotechnology company based in Canada. The company focuses on the development of drug delivery technology that enhances the performance and effectiveness of pharmaceuticals. Lexaria's patented DehydraTECH platform uses lipid-based carriers to deliver drugs and other bioactive compounds more efficiently into the bloodstream. This technology has shown potential in improving the delivery of various substances, including cannabinoids, nicotine, and nonsteroidal anti-inflammatory drugs. Lexaria is actively involved in partnerships and collaborations with other companies to develop and commercialize products utilizing its technology. The company aims to provide improved delivery solutions that can enhance the effectiveness and consumer experience of various pharmaceuticals and nutraceuticals.


   Company Address: #100 ? 740 McCurdy Road Kelowna 0
   Company Phone Number: 765.6424   Stock Exchange / Ticker: NASDAQ LEXX
   LEXX is expected to report next financial results on April 13, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Lexaria Bioscience Corp

Lexaria Bioscience Corp's Game-Changing Drug-Delivery System Unveiled, Unlocking the Future of Medical Treatments

Lexaria Bioscience Corp (NASDAQ: LEXX) has recently unveiled its groundbreaking proprietary drug-delivery system, signaling a potential revolution in medical treatments. This innovative technology offers new possibilities for GLP-1 Diabetes and weight-loss drugs, presenting a solution to some of the most significant challenges in the pharmaceutical industry. While the company reported a cumulative net loss of $-8 million in the fourth quarter of 2023, its drug-delivery system holds promise for long-term success.
Lexaria's drug-delivery system has the potential to transform the way molecules enter the bloodstream, offering an exciting avenue for revolutionary cures. By addressing the challenges faced by traditional drug delivery methods, Lexaria aims to provide more effective and efficient treatments for a range of medical conditions.

Management Announcement

Lexaria Bioscience Corp's Revolutionary Drug-Delivery System: The Future of Medical Breakthroughs and Profitability.

Published Thu, Jan 11 2024 1:30 PM UTC

as Profitable: Lexaria Bioscience's Breakthrough Drug-Delivery System Revolutionizes Medical Treatments
Lexaria Bioscience Corp. (NASDAQ: LEXX) has recently revealed its groundbreaking proprietary drug-delivery system, which has the potential to revolutionize the way molecules enter the bloodstream and offer exciting new possibilities for GLP-1 Diabetes and weight-loss ...

Management Announcement

Lexaria Bioscience Corp. Revolutionizes Drug Delivery for Type 2 Diabetes Treatment

Published Tue, Jan 9 2024 1:30 PM UTC

Lexaria Bioscience Corp. (NASDAQ: LEXX) has recently announced an exciting breakthrough in drug delivery technology, elevating the efficacy and delivery of GLP-1 agonists through its proprietary platform. The company's achievements have been highlighted in an editorial published by NetworkNewsWire, a leading financial news and content distribution platform.
The innovativ...

Lexaria Bioscience Corp

Vanishing Deficit: Lexaria Bioscience Corp's Remarkable Financial Turnaround Signals a Promising Future 2.

Lexaria Bioscience Corp, a renowned pharmaceutical company, has recently showcased a significant improvement in its financial performance. In the most recent fiscal period, the company successfully reduced its loss per share to $-0.12 per share, a notable improvement compared to $-0.25 per share in the same period last year. This positive development highlights the company's efforts in enhancing its profitability and financial stability.
Moreover, Lexaria Bioscience Corp's performance in the preceding financial reporting period was even more impressive. In this period, the company reported a loss per share of $-0.37, which demonstrates a substantial decrease from their previous financial reporting period. This remarkable achievement further emphasizes the company's commitment to enhancing its financial performance and efficiency.

Lexaria Bioscience Corp

Lexaria Bioscience Corp Reports Increased Deficit Per Share and Decrease in Revenue for Q3 2023


Introduction:
Lexaria Bioscience Corp, a pioneering biotechnology company specializing in innovative drug delivery platforms, recently released its financial results for the fiscal interval ending May 31, 2023. The company experienced an increase in its deficit per share and a decline in revenue, raising concerns amongst investors. However, encouraging trends in the company's stock performance suggest potential for future growth.
Fiscal Performance:
For the fiscal period ending May 31, 2023, Lexaria Bioscience Corp reported a deficit per share of $-0.37, indicating a decline compared to $0.00 per share from the previous year. Moreover, this represents a widening deficit from $-0.22 per share in the preceding reporting period. The decrease in revenue was also notable with a decline of -6.586% to $0.09 million from $0.10 million in the corresponding reporting period a year ago. However, a positive sequential development was seen, with revenue doubling by 166.029% from $0.04 million.






 

Lexaria Bioscience's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com